OncoSec Medical Incorporated
Other OTCTotal Valuation
OncoSec Medical Incorporated carries a market capitalization of 596.00, placing it among publicly traded companies globally. Its enterprise value stands at 232,964.45, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 596.00 |
| Enterprise Value | 232,964.45 |
Share Statistics
OncoSec Medical Incorporated currently has 2.97M shares outstanding.
| Shares Outstanding | 2.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.08 |
| P/FCF Ratio | -0.02 |
| P/OCF Ratio | -0.02 |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 42,552.62 |
Financial Position
OncoSec Medical Incorporated maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.14, indicating conservative leverage, while an interest coverage ratio of -608.38 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.51 |
| Debt / Equity | -63.14 |
| Debt / EBITDA | -0.11 |
| Interest Coverage | -608.38 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -133.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -3.33M |
| Effective Tax Rate | N/A |
Stock Price Statistics
OncoSec Medical Incorporated's stock has gained approximately 900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -31.72M, while operating income came in at -32.65M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -32.65M |
| Pretax Income | -32.72M |
| Net Income | -29.39M |
| EBITDA | -31.72M |
| EBIT | -32.65M |
| Earnings Per Share (EPS) | -14.30 |
Balance Sheet
OncoSec Medical Incorporated holds 3.68M in cash and equivalents against 3.46M in total debt, resulting in a net debt position of -1.39M. Total book value stands at -300.88M, with working capital of -789,468.00 providing operational flexibility.
| Cash & Cash Equivalents | 3.68M |
| Total Debt | 3.46M |
| Net Debt | -1.39M |
| Equity (Book Value) | -300.88M |
| Book Value Per Share | -146.42 |
| Working Capital | -789,468.00 |
Cash Flow
OncoSec Medical Incorporated produced -24.99M in operating cash flow over the past twelve months.
| Operating Cash Flow | -24.99M |
| Capital Expenditures | N/A |
| Free Cash Flow | -24.99M |
| FCF Per Share | -12.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -783.75 |
| FCF Yield | -5,528.76 |
Stock Splits
OncoSec Medical Incorporated's most recent stock split took place on November 9, 2022 with a 22:1 split ratio.
| Last Split Date | 11/9/2022 |
| Split Ratio | 22:1 |
Scores
OncoSec Medical Incorporated posts an Altman Z-Score of -62.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -62.12 |